Articles related to CLINICAL TRIALS

In a significant shift, a new phase 3 trial suggests reconsidering adjuvant radiotherapy after radical prostatectomy, as many patients may not require it long-term, potentially reducing morbidity risks.

The significant reduction in the incidence of death from cardiovascular causes, nonfatal MI, or nonfatal stroke highlights the need for further research into the benefits of semaglutide in this patient population.

Groundbreaking research reveals ketamine’s potential as an effective alternative to ECT in treating treatment-resistant depression, offering new hope to millions.

Uncover the groundbreaking advancements in PNH treatment, from oral therapies to dual inhibition strategies, and their implications for patient outcomes.

The recent phase 3 trial has demonstrated that the combination of the KRAS G12C inhibitor, sotorasib, with the EGFR inhibitor, panitumumab, can lead to longer progression-free survival in patients with chemorefractory metastatic colorectal cancer.

The study’s findings suggest that ibrutinib–venetoclax therapy could potentially revolutionize the treatment of CLL. With a significant reduction in disease progression or death at a median of 43.7 months, this therapy could offer a promising alternative to the standard FCR regimen.